Edition:
United Kingdom

Catalyst Biosciences Inc (CBIO.OQ)

CBIO.OQ on NASDAQ Stock Exchange Capital Market

27.04USD
21 May 2018
Change (% chg)

$-1.23 (-4.35%)
Prev Close
$28.27
Open
$28.74
Day's High
$28.85
Day's Low
$26.72
Volume
42,811
Avg. Vol
82,054
52-wk High
$37.00
52-wk Low
$3.13

Chart for

About

Catalyst Biosciences, Inc., formerly Targacept, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and... (more)

Overall

Beta: 2.08
Market Cap(Mil.): $334.18
Shares Outstanding(Mil.): 11.94
Dividend: --
Yield (%): --

Financials

  CBIO.OQ Industry Sector
P/E (TTM): -- 28.57 32.53
EPS (TTM): -5.70 -- --
ROI: -28.65 13.08 12.63
ROE: -33.72 14.80 14.50

BRIEF-Catalyst Biosciences Reports Q1 Loss Per Share $0.56

* CATALYST BIOSCIENCES REPORTS FIRST QUARTER OPERATING & FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

03 May 2018

BRIEF-Catalyst Biosciences Receives $1.5 Million For Neuronal Nicotinic Receptor Asset

* CATALYST BIOSCIENCES RECEIVES $1.5 MILLION IN TWO MILESTONE PAYMENTS FOR NEURONAL NICOTINIC RECEPTOR (NNR) ASSET Source text for Eikon: Further company coverage:

26 Mar 2018

BRIEF-Catalyst Biosciences Provides Corporate Update

* CATALYST BIOSCIENCES REPORTS FOURTH QUARTER AND FULL-YEAR 2017 OPERATING & FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

01 Mar 2018

BRIEF-Catalyst Biosciences Announces Manufacturing Agreement With AGC Biologics For Subcutaneous Factor IX Product CB 2679D

* CATALYST BIOSCIENCES ANNOUNCES MANUFACTURING AGREEMENT WITH AGC BIOLOGICS FOR SUBCUTANEOUS FACTOR IX PRODUCT CB 2679D

26 Feb 2018

BRIEF-Catalyst Biosciences Says Public Offering Of 2.94 Mln Common Shares Priced At $34/Share

* CATALYST BIOSCIENCES ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

13 Feb 2018

BRIEF-Catalyst Biosciences Announces Proposed Public Offering Of Common Stock

* CATALYST BIOSCIENCES ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

12 Feb 2018

BRIEF-RTW Investments Reports A 5.71 Percent Passive Stake In Catalyst Biosciences

* RTW INVESTMENTS, LP REPORTS A 5.71 PERCENT PASSIVE STAKE IN CATALYST BIOSCIENCES AS OF JAN 26, 2018 Source text: (http://bit.ly/2nDJSqt) Further company coverage:

05 Feb 2018

BRIEF-Catalyst Biosciences Files For Mixed Shelf Of Up To $150 Mln

* CATALYST BIOSCIENCES INC FILES FOR MIXED SHELF OF UP TO $150 MILLION - SEC FILING Source text - http://bit.ly/2F2CQC6 Further company coverage:

22 Jan 2018

BRIEF-Catalyst Biosciences Initiates Phase 2/3 Trial Of Marzeptacog Alfa (Activated)

* CATALYST BIOSCIENCES INITIATES PHASE 2/3 TRIAL OF MARZEPTACOG ALFA (ACTIVATED) FOR PROPHYLAXIS IN HEMOPHILIA A OR B WITH INHIBITORS

04 Jan 2018

BRIEF-Nexthera Capital Reports 5.4 Pct Passive Stake In Catalyst Biosciences

* NEXTHERA CAPITAL REPORTS A 5.4 PERCENT PASSIVE STAKE IN CATALYST BIOSCIENCES AS OF DEC 20 - SEC FILING Source text : (http://bit.ly/2l9OsLV) Further company coverage:

27 Dec 2017

Competitors

Earnings vs. Estimates